9 completed, 4 recruiting, 4 unknown, 2 terminated. 22 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Completed 9, Recruiting 4, Unknown 4, Terminated 2, Active not recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 6 | Recruiting 3, Unknown 2, Active not recruiting 1 |
Follow Latent Infection: new trials by email Literature Review of Latent Infection trials Research Report on Latent Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 2530 | 2026-05-08 | 2026-10-20 |
| Shorter and Safer Treatment Regimens for Latent TB rifampin standard arm, rifampin double dose, levofloxacin and rifapentine - Tuberculosis Infection, Latent | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 1800 | 2025-06-10 | 2026-05-11 |
| 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam Isoniazid, Rifapentine, Rifampicin - Tuberculosis Infection | Phase 3 | Withdrawn | Freundeskreis Für Internationale Tuberkulosehilfe e.V | 2024-11-01 | 2026-09-09 | |
| BCG Revaccination in Children and Adolescents BCG vaccine, Oral Chemoprophylaxis - Tuberculosis Infection, Tuberculosis | Phase 3 | Suspended | Tuberculosis Research Centre, India | 9200 | 2024-07-15 | 2023-12-18 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study) isoniazid and rifapentine, Rifampin and Isoniazid - Tuberculosis, Latent Tuberculosis | Phase 3 | Recruiting | Huashan Hospital | 3520 | 2023-09-01 | 2026-07-14 |
| Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above Recombinant Mycobacterium Tuberculosis Fusion Protein, Purified Protein Derivative of Tuberculin - Latent Tuberculosis Infection | Phase 3 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 780 | 2023-08-03 | 2026-04-30 |
| Immunization With BCG Vaccine to Prevent Tuberculosis Infection BCG (Tokyo 172) vaccine, Placebo - Tuberculosis Infection | Phase 3 | Terminated | Henry M. Jackson Foundation for the Advancement of Military Medicine | 16 | 2021-12-01 | 2026-01-23 |
| Alternative Antibiotics for Syphilis Linezolid 600 mg (post-interim), Benzathine Penicilllin G (post-interim) - Early Latent Syphilis, Primary Syphilis | Phase 3 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 165 | 2021-10-14 | 2026-07-29 |
| Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis Cyclophosphamide injection - Tuberculosis, Tubercular Meningitis | Phase 2 / Phase 3 | Unknown | All India Institute of Medical Sciences | 40 | 2021-01-01 | 2020-12-30 |
| Risk of SDRs Under 3HP and 1HP Regimen for LTBI isoniazid and rifapentine - Latent Tuberculosis Infection | Phase 3 | Completed | National Taiwan University Hospital | 490 | 2019-09-24 | 2023-12-26 |
| Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks - Latent Tuberculosis | Phase 2 / Phase 3 | Recruiting | Centers for Disease Control and Prevention | 3400 | 2019-08-01 | 2026-05-06 |
| Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren Cholecalciferol, Placebo - Latent Tuberculosis | Phase 3 | Completed | Queen Mary University of London | 1743 | 2017-03-14 | 2022-09-08 |
| Efficacy of Nyaditum Resae(R) Against Active TB in Georgia Nyaditum resae(R), Placebo - Close Contacts of Active Tuberculosis | Phase 2 / Phase 3 | Unknown | Fundació Institut Germans Trias i Pujol | 3300 | 2017-03-10 | 2017-09-07 |
| Vitamin D Supplementation in TB Prevention Cholecalciferol (vitamin D3), Placebo - Latent Tuberculosis | Phase 3 | Completed | Harvard School of Public Health (HSPH) | 8851 | 2015-09-01 | 2020-07-16 |
| Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan Rifapentine and Isoniazid for 3 months, Isoniazid for 9 months - Latent Tuberculosis Infection | Phase 3 | Unknown | National Taiwan University Hospital | 283 | 2014-08-01 | 2016-12-15 |
| Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine - Latent Tuberculosis Infection | Phase 3 | Completed | Centers for Disease Control and Prevention | 1002 | 2012-09-01 | 2025-03-13 |
| "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". Levofloxacin, Isoniazid - Latent Tuberculosis Infection, Infection in Solid Organ Transplant Recipients | Phase 3 | Terminated | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 68 | 2012-01-01 | 2014-08-06 |
| Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9) Isoniazid, Rifampin - Latent Tuberculosis Infection | Phase 3 | Completed | McGill University | 844 | 2011-08-01 | 2017-12-19 |
| Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) 4-month rifampin vs. 9-month isoniazid - Latent Tuberculosis Infection | Phase 3 | Unknown | National Taiwan University Hospital | 300 | 2011-05-01 | 2011-07-20 |
Showing 20 of 22. Sign in to see all of them.
Latent Tuberculosis (21) · Tuberculosis (9) · Arachnoiditis (1) · Mycobacterium Infections (1) · Syphilis (1) · Syphilis, Latent (1) · Syphilis, primary (1) · Syphilis, secondary (1) · Treponemal Infections (1) · Tuberculosis, Meningeal (1) · Tuberculosis, Pulmonary (1)
Bacterial Infections (22) · Bacterial Infections and Mycoses (22) · Infections (22) · Actinomycetales Infections (21) · Gram-Positive Bacterial Infections (21) · Mycobacterium Infections (20) · Tuberculosis (12) · Central Nervous System Bacterial Infections (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Gram-Negative Bacterial Infections (1) · Lung Diseases (1)
Isoniazid (11) · rifapentine (8) · Rifampin (6) · Levofloxacin (3) · Cholecalciferol (2) · Moxifloxacin (2) · bedaquiline (2) · BCG Vaccine (1) · Chemoprevention (1) · Clarithromycin (1) · Cyclophosphamide (1) · Ethambutol (1) · Linezolid (1) · OPC-67683 (1) · Pyrazinamide (1)
Centers for Disease Control and Prevention (3) · National Taiwan University Hospital (3) · McGill University (2) · All India Institute of Medical Sciences (1) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1) · Centre Hospitalier Universitaire, Amiens (1) · Freundeskreis Für Internationale Tuberkulosehilfe e.V (1) · Fundació Institut Germans Trias i Pujol (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Harvard School of Public Health (HSPH) (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1) · Huashan Hospital (1) · Johns Hopkins University (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1)
Canada (5) · Benin (4) · South Africa (4) · United States (4) · Vietnam (4) · Australia (3) · Brazil (3) · China (3) · Indonesia (3) · Spain (3) · Taiwan (3) · Uganda (3) · Ghana (2) · Guinea (2) · Haiti (2)
Dick Menzies, MD (3) · Robert Belknap, MD (2) · Aishwarya Venkataraman, MRCPCH (1) · Amber Robinson, PhD (1) · Andrey S Borisov, MD, MPH (1) · Daniel W Fitzgerald, MD (1) · Davaasambuu Ganmaa, MD PhD (1) · Dick Menzies, MD, MSc (1) · Ekaterina V Kurbatova, MD, PhD, MPH (1) · Eric Nuermberger, MD (1) · Jann-Yuan Wang, MD, PhD (1)
PMID 31866327, PMID 32539440, PMID 32785709, PMID 36949623, PMID 20627913, PMID 25404412, PMID 28043488, PMID 29114781, PMID 29393655, PMID 30029896, PMID 30067928, PMID 30067931, PMID 32706534, PMID 36441522, PMID 36730240, PMID 36815322, PMID 38048799, PMID 38211601, PMID 38599800, PMID 38996972, PMID 39345833, PMID 40326358, PMID 40915316, PMID 42247627